Jacquelyn M Powers1, Mark Shamoun2, Timothy L McCavit3, Leah Adix4, George R Buchanan5. 1. Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX; Department of Pediatrics, Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX. Electronic address: Jacquelyn.Powers@bcm.edu. 2. Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX; Children's Health, Dallas, TX. 3. Division of Hematology/Oncology, Cook Children's Hospital, Fort Worth, TX; Department of Pediatrics, Cook Children's Hospital, Fort Worth, TX. 4. Children's Health, Dallas, TX. 5. Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX; Children's Health, Dallas, TX; Division of Hematology/Oncology, The University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
OBJECTIVE: To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). STUDY DESIGN: In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. RESULTS: A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. CONCLUSION: FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
OBJECTIVE: To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). STUDY DESIGN: In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. RESULTS: A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. CONCLUSION:FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
Authors: Susan E Kirk; Michael E Scheurer; Melanie Brooke Bernhardt; Donald H Mahoney; Jacquelyn M Powers Journal: Am J Hematol Date: 2021-04-07 Impact factor: 13.265
Authors: Luigi Cirillo; Chiara Somma; Marco Allinovi; Alfredo Bagalà; Giuseppe Ferro; Elio Di Marcantonio; Stefania Bellelli; Lorenzo Antonio Dallari; Piercarlo Ballo; Pietro Claudio Dattolo Journal: Sci Rep Date: 2021-04-02 Impact factor: 4.379
Authors: Sarah H O'Brien; Sherif M Badawy; Seth J Rotz; Mona D Shah; Julie Makarski; Rachel S Bercovitz; Mary-Jane S Hogan; Lori Luchtman-Jones; Julie A Panepinto; Ginna M Priola; Char M Witmer; Julie A Wolfson; Marianne Yee; Lisa K Hicks Journal: Blood Adv Date: 2022-01-25
Authors: Chiara Udina; Maria Andrea Lanzetta; Fulvio Celsi; Egidio Barbi; Giulia Gortani; Matteo Bramuzzo; Grazia Di Leo Journal: Children (Basel) Date: 2022-03-09